Recent Updates
Recently added Catalysts
MNKD

MannKind Receives $16.7 Million From Sale of Valencia Property

Key Takeaway: VALENCIA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $16.7 million on February 17, 2017, upon closing the sale of real estate owned by the Company in Valencia, California, net of closing costs. About

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

VALENCIA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $16.7 million on February 17, 2017, upon closing the sale of real estate owned by the Company in Valencia, California, net of closing costs.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Last updated: Feb 21, 2017